{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:18:48Z","timestamp":1770884328234,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Histiocytic sarcoma (HS) is a rare hematological malignancy with limited treatment options, and it is also prone to complications such as hemophagocytic lymphohistiocytosis (HLH) in the later stages of the disease, leading to difficulties in treatment and poor prognosis. It highlights the importance of developing novel therapeutic agents. Herein, we present a case of a 45-year-old male patient who was diagnosed with PD-L1-positive HS with HLH. The patient was admitted to our hospital with recurrent high fever, multiple skin rashes with pruritus throughout the body and enlarged lymph nodes. Subsequently, pathological biopsy of the lymph nodes revealed high expression of CD163, CD68, S100, Lys and CD34 in the tumor cells and no expression of CD1a and CD207, confirming this rare clinical diagnosis. Concerning the low remission rate by conventional treatment in this disease, the patient was administered with sintilimab (an anti-programmed cell death 1 [anti-PD-1] monoclonal antibody) at 200 mg\/d combined with a first-line chemotherapy regimen for one cycle. Further exploration of pathological biopsy by using next-generation gene sequencing led to the use of targeted therapy of chidamide. After one cycle of combination therapy (chidamide+sintilimab, abbreviated as CS), the patient achieved a favorable response. The patient showed remarkable improvement in the general symptoms and laboratory examination results (e.g., elevated indicators of inflammation); even the clinical benefits was not persistent, he survived one more month after his cessation of treatment by himself due to economic difficulty. Our case suggests that PD-1 inhibitor coupled with targeted therapy might constitute a potential therapeutic option for primary HS with HLH.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1127599","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T04:34:07Z","timestamp":1678250047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingli","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)61048-x","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1532\/ijh97.07012","article-title":"Nationwide survey of hemophagocytic lymphohistiocytosis in Japan","volume":"86","author":"Ishii","year":"2007","journal-title":"Int J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-551622","article-title":"How I treat hemophagocytic lymphohistiocytosis in the adult patient","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3390\/diagnostics11020310","article-title":"Histiocytic sarcoma: Challenging course, dismal outcome","volume":"11","author":"Andersen","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B8","article-title":"Histiocytic sarcoma","volume":"22","author":"Tocut","year":"2020","journal-title":"Isr Med Assoc J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13014-018-1115-x","article-title":"Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1\/PD-L2 expression and literature review","volume":"13","author":"May","year":"2018","journal-title":"Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0053","article-title":"Histiocytic neoplasms, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Go","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000001524","article-title":"PD-1 and PD-L1 immunohistochemistry as a diagnostic tool for classic Hodgkin lymphoma in small-volume biopsies","volume":"44","author":"Volaric","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11899-018-0432-3","article-title":"The future of combination therapies for peripheral T cell lymphoma (PTCL)","volume":"13","author":"Ma","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1496","article-title":"Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations","volume":"5","author":"Montalvo","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04190-4","article-title":"Histiocytic sarcoma progressing from follicular lymphoma and mimicking acquired hemophagocytic lymphohistiocytosis","volume":"99","author":"Sch\u00fcnemann","year":"2020","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e3181897e8e","article-title":"Malignant histiocytoses\/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor","volume":"17","author":"Shinoda","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/dc.22974","article-title":"Hemophagocytosis in an adrenal aspirate: histiocytic sarcoma","volume":"42","author":"Singh","year":"2014","journal-title":"Diagn Cytopathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-7-143","article-title":"Primary splenic histiocytic sarcoma complicated with prolonged idiopathic thrombocytopenia and secondary bone marrow involvement: a unique surgical case presenting with splenomegaly but non-nodular lesions","volume":"7","author":"Yamada","year":"2012","journal-title":"Diagn Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102063","article-title":"CLIPPERS, a syndrome of lymphohistiocytic disorders","volume":"42","author":"Li","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25523","article-title":"Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"62","author":"Alten","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000002515","article-title":"Mediastinal germ cell tumor-associated histiocytic proliferations treated with thalidomide plus chemotherapy followed by alemtuzumab-containing reduced intensity allogeneic peripheral blood stem cell transplantation: A case report","volume":"95","author":"Fang","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-812495","article-title":"Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes","volume":"131","author":"Kommalapati","year":"2018","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0349-RS","article-title":"Histiocytic sarcoma","volume":"144","author":"Hung","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1281122","article-title":"Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0220-RA","article-title":"Histiocytic sarcoma: Review, discussion of transformation from b-cell lymphoma, and differential diagnosis","volume":"142","author":"Skala","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0200-x","article-title":"Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma","volume":"32","author":"Shanmugam","year":"2019","journal-title":"Mod Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230375","article-title":"Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.6004\/jnccn.2022.7001","article-title":"Near complete response to trametinib treatment in histiocytic sarcoma harboring a somatic KRAS mutation","volume":"20","author":"Hu","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2553-9","article-title":"A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib","volume":"109","author":"Kumamoto","year":"2019","journal-title":"Int J Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e28200","DOI":"10.1002\/pbc.28200","article-title":"Secondary histiocytic sarcoma with BRAF(V600E) mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib","volume":"67","author":"Venkataraman","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1511490","article-title":"Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation","volume":"378","author":"Gounder","year":"2018","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1492128","article-title":"Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma","volume":"60","author":"Kommalapati","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.717082","article-title":"Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma","volume":"54","author":"Zeidan","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.32.6603","article-title":"Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature","volume":"29","author":"Gergis","year":"2011","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discovery"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant erdheim-Chester disease and langerhans cell histiocytosis: Analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27491","article-title":"Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma","volume":"66","author":"Bose","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003886","article-title":"Nivolumab treatment of relapsed\/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults","volume":"135","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001696","article-title":"Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma","volume":"9","author":"Que","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682436","article-title":"A novel mechanism of action of histone deacetylase inhibitor chidamide: Enhancing the chemotaxis function of circulating PD-1(+) cells from patients with PTCL","volume":"11","author":"Wei","year":"2021","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.608304","article-title":"Durable response to sintilimab and chidamide in a patient with pegaspargase- and immunotherapy-resistant NK\/T-cell lymphoma: Case report and literature review","volume":"10","author":"Yan","year":"2020","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8879448","article-title":"Triplet therapy with PD-1 blockade, histone deacetylase inhibitor, and DNA methyltransferase inhibitor achieves radiological response in refractory double-expressor diffuse Large b-cell lymphoma with 17p deletion","volume":"2020","author":"Zheng","year":"2020","journal-title":"Case Rep Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1127599\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T04:34:11Z","timestamp":1678250051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1127599\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2023.1127599"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1127599","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"article-number":"1127599"}}